Covaxin shows 77.8% efficacy in phase 3 trial data: All you need to know | Covid | Hindustan Times
close_game
close_game

Covaxin shows 77.8% efficacy in phase 3 trial data: All you need to know | Covid

Bharat Biotech's Covaxin has shown 77.8 per cent efficacy after the Subject Expert Committee (SEC) under the drug regulator reviewed its Phase III trials data on Tuesday. The Hyderabad-based COVID vaccine manufacturing company had submitted data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the weekend. Bharat Biotech's 'pre-submission' meeting with the World Health Organization (WHO) will take on Wednesday for the approval for Covaxin. Watch the full video for more details.

 
SHARE
Story Saved
Live Score
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Saturday, May 25, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On